Compare Ecopetrol SA (EC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Recursion Pharmaceuticals Inc — how do they compare? Ecopetrol SA trades at $17.07 (market cap $33.11B), while Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B). The key difference: Ecopetrol SA is far larger — about 15.5× Recursion Pharmaceuticals Inc's market cap, and Ecopetrol SA pays a 3.83% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EC | RXRX | |
|---|---|---|
Market Cap | $33.11B | $2.14B |
Volume | 993,598 | 30,789,535 |
Sector | Energy | Health |
52-Week High | $18.26 | $6.79 |
52-Week Low | $8.61 | $2.84 |
Typical Hold Time | 84 Days | 22 Days |
Enterprise Value | $61.36B | $1.66B |
Dividend Yield | 3.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.63, down 1.95% amid bearish technical signals and recent earnings misses. The stock shows attractive valuation metrics with P/E of 7.97 and P/S of 0.91, but faces declining revenue trends from $159.6B in 2022 to $119.7B in 2025. Recent management changes and board restructuring under Colombia's new government create uncertainty, while analyst sentiment remains cautious with 27% buy ratings.
The outlook remains challenged by declining profitability and political interference risks, though current valuations appear discounted. Investment opportunity exists if new management can stabilize operations, but investors face headwinds from earnings volatility and geopolitical factors in Colombia's state-controlled energy sector.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
